Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.40 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2595316 | 1.00 | KCNH2 (0.44) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL14773850 | 1.00 | KCNH2 (0.44) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL16181564 | 0.91 | HSD17B10 (0.46) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL14773851 | 0.90 | KCNH2 (0.43) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL2595984 | 0.90 | KCNH2 (0.43) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL1947682 | 0.90 | KCNH2 (0.43) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL17188207 | 0.89 | TDP1 (0.47) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL12306317 | 0.88 | KCNH2 (0.35) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL14959764 | 0.88 | KCNH2 (0.35) | KCNH2NR1I2PPARGPTGS1PGR | |
| SCHEMBL12334100 | 0.88 | KCNH2 (0.35) | KCNH2NR1I2PPARGPTGS1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499566-B2 | Oxidation process for preparing 3-formyl-cephem derivatives | Basilea Pharmaceutica International (CH) | 2016-11-22 | — | — | US | disclosed |
| US-20150218189-A1 | Oxidation Process For Preparing 3-Formyl-Cephem Derivatives | BASILEA PHARMACEUTICA AG | 2015-08-06 | — | — | US | disclosed |
| US-9006422-B2 | Oxidation process for preparing 3-formyl-cephem derivatives | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2015-04-14 | — | — | US | disclosed |
| EP-2569321-B1 | OXIDATION PROCESS FOR PREPARING 3-FORMYL-CEPHEM DERIVATIVES | BASILEA PHARMACEUTICA INTERNAT LTD (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2569321-A1 | OXIDATION PROCESS FOR PREPARING 3-FORMYL-CEPHEM DERIVATIVES | Basilea Pharmaceutica International Ltd. (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-20130066065-A1 | OXIDATION PROCESS FOR PREPARING 3-FORMYL-CEPHEM DERIVATIVES | Basilea Pharmaceutica International (CH) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141415-A1 | OXIDATION PROCESS FOR PREPARING 3-FORMYL-CEPHEM DERIVATIVES | BASILEA PHARMACEUTICA INTERNATIONAL LTD. (CH) | 2011-11-17 | — | — | WO | disclosed |
| EP-1435357-B1 | New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives | BASILEA PHARMACEUTICA AG (CH) | 2010-03-17 | — | — | EP | disclosed |
| EP-1289998-B1 | NEW PROCESS FOR THE PREPARATION OF VINYL-PYRROLIDINONE CEPHALOSPORINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| EP-1435357-A2 | New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives | Basilea Pharmaceutica AG (CH) | 2004-07-07 | — | — | EP | disclosed |
| US-6504025-B2 | In fewer steps and is obtained in higher yield; chemical intermediates; useful in treating methicillin resistent Staphylococcus aureus and Pseudomonas aeruginosa | BASILEA PHARMACEUTICA AG (CH) | 2003-01-07 | — | — | US | disclosed |
| US-20020019381-A1 | Process for the preparation of vinyl-pyrrolidinone cephalosporin derivatives | BASILEA PHARMACEUTICA AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066065-A1 | OXIDATION PROCESS FOR PREPARING 3-FORMYL-CEPHEM DERIVATIVES | MAOB, TET2, TET1 | KCNH2 987/4885NR1I2 4537/4885PPARG 3006/4885 |
| US-20150218189-A1 | Oxidation Process For Preparing 3-Formyl-Cephem Derivatives | MAOB, TET2, TET1 | KCNH2 987/4885NR1I2 4537/4885PPARG 3006/4885 |
| US-20020019381-A1 | Process for the preparation of vinyl-pyrrolidinone cephalosporin derivatives | DHPS, PEPD, VAT1 | KCNH2 2122/4885NR1I2 3183/4885PPARG 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.